Biggest Stock Losers Today

HEARTSCIENCES ANNOUNCES GRANT OF FUNDAMENTAL PATENT BY THE EUROPEAN PATENT OFFICE COVERING ASSESSMENT OF DIASTOLIC FUNCTION OF THE HEART USING AI-ECG

News

patent covers use of ai-ecg for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease patent covers use of ai-ecg for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease

EDIBLE GARDEN REPORTS SIGNIFICANT 27.6% YEAR-OVER-YEAR REVENUE GROWTH FOR FIRST QUARTER OF 2024

News

195.8% gross profit increase in q1 2024 with gross margin increasing by 171 basis points 95% of edible garden fresh product line being produced at company-owned facilities - strategic pivot away from third-party growers marks a turn toward higher expected profits vertical integration expected to pay off - company plans to boost margins in the coming quarters conference call to be held today at 8:00 am et. belvidere, n.j.

BETTER CHOICE COMPANY ANNOUNCES FIRST QUARTER 2024 RESULTS

News

eps growth of 28% year over year to $(3.60) adjusted ebitda 1 growth of 27% year over year to $(1.4) million adjusted ebitda margin 1 of (18)% , a 299 basis point expansion year over year

AEYE REPORTS FIRST QUARTER 2024 RESULTS

News

dublin, calif.--(business wire)--aeye, inc. (nasdaq: lidr), a global leader in adaptive, high performance lidar solutions, today announced its results for the first quarter ended march 31, 2024. management commentary “aeye made incredible progress with our capital-light partnership model in the first quarter, including significantly expanding our strategic opportunities and opening the door to the booming lidar market in china. the first product from our 4sight flex reference design, apollo, ha.

XBP EUROPE HOLDINGS, INC. REPORTS FIRST QUARTER 2024 RESULTS

News

first quarter highlights ●  revenue of $40.4 million, down 5.7% year-over-year (7.3% on a constant currency basis)●  gross margin grew to 24.6%, a 270 bps increase sequentially and 250 bps increase year-over-year●  net loss of $2.2 million includes $0.8 million of fx losses       ●  high margin technology segment grew to 28.4% of revenues, a 120 bps increase sequentially and 690 bps increase year-over-year●  awarded a multi-year contract with his majesty's passport office (“hmpo”) for a nationwide project in the uk with a total contract value (“tcv”) of approximately $40 million london and santa monica, calif., may 13, 2024 (globe newswire) -- xbp europe holdings, inc. (“xbp europe” or the “company”) (nasdaq: xbp), a pan-european integrator of bills, payments, and related solutions and services seeking to enable the digital transformation of its clients, announced today its financial results for the first quarter ended march 31, 2024.

GAMESTOP ANNOUNCES FIRST QUARTER PRELIMINARY RESULTS

News

grapevine, texas, may 17, 2024 (globe newswire) -- gamestop corp. (nyse: gme) (“gamestop” or the “company”) today announced certain preliminary unaudited financial information for the first quarter ended may 4, 2024.

DERMATA THERAPEUTICS ANNOUNCES EXERCISE OF WARRANTS FOR $2.66 MILLION IN GROSS PROCEEDS PRICED AT-THE-MARKET UNDER NASDAQ RULES

News

san diego, ca / accesswire / may 17, 2024 / dermata therapeutics, inc. (nasdaq:drma)(nasdaq:drmaw) ("dermata," or the "company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the company's common stock, having exercise prices of $9.7665 and $32.40 per share, issued by dermata in november 2023 (with respect to 462,945 warrants) and may 2023 (with respect to 53,391 warrants), at a reduced exercise price of $5.16 per share. the shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on form s-3 (file no.

AIRSHIP AI REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

News

strong first quarter 2024 net revenues of $10.6 million support fiscal year 2024 triple-digit revenue growth & positive cash flow objectives first quarter 2024 net revenues of $10.6 million represent 84.5% of the company's full year revenue in 2023 awarded second contract by doj agency for $2.35 million for company's outpost ai appliance to support emerging public safety and investigative requirements redmond, wa., may 15, 2024 (globe newswire) -- airship ai holdings, inc. (nasdaq: aisp) (“airship ai” or the “company”), a leader in ai-driven video, sensor, and data management surveillance solutions, today reported its financial and operational results for the first quarter ended march 31, 2024.

CERENCE ANNOUNCES SECOND QUARTER FISCAL YEAR 2024 RESULTS

News

headlines q2 revenue above the high end of the guidance range due to oem-related adjustments; however, company lowering its fy24 guidance and withdrawing its multi-year plan included in q2 results is a goodwill impairment charge of approximately $252 million company believes that initial success with new generative ai products, including six design wins, and early validation of its next-gen platform will provide a solid foundation to reinvigorate future growth burlington, mass., may 09, 2024 (globe newswire) -- cerence inc. (nasdaq: crnc), ai for a world in motion, today reported its second quarter fiscal year 2024 results for the quarter ended march 31, 2024.

SIYATA MOBILE REPORTS SIGNIFICANT 30% YEAR-OVER-YEAR REVENUE GROWTH FOR THE FIRST QUARTER OF 2024

News

gross margin expands to 36.6%, up from 27.5% in the year ago period vancouver, bc / accesswire / may 16, 2024 / siyata mobile inc. (nasdaq:syta)(nasdaq:sytaw) (" siyata " or the " company "), a global vendor of push-to-talk over cellular (poc) devices announced its financial results for the three months ended march 31, 2024. marc seelenfreund, ceo of siyata, said, "with revenue growth of 30%, a higher gross margin and solid improvement in adjusted ebitda, our first quarter financial results reflect improvement in our business and the traction we are gaining in the market.

PROTARA THERAPEUTICS ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

News

new york, may 02, 2024 (globe newswire) -- protara therapeutics, inc. (nasdaq: tara), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended march 31, 2024 and provided a business update.

DXC TECHNOLOGY AND FERROVIAL TO CO-CREATE NEW GENERATIVE ARTIFICIAL INTELLIGENCE PLATFORM

News

quercus will help organizations adopt generative ai to accelerate innovation and optimize business processes ashburn, va. , may 17, 2024 /prnewswire/ -  dxc technology  (nyse: dxc), a leading fortune 500 global technology services provider, will work with ferrovial (nasdaq: fer), one of the world's leading infrastructure companies, and microsoft to jointly develop the generative artificial intelligence (ai) platform quercus.

ARCA BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES MERGER OF ARCA BIOPHARMA, INC. - ABIO

News

new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed merger of arca biopharma, inc. (the “company”) (nasdaqcm: abio) and oruka therapeutics. upon closing of the proposed transaction, arca shareholders are expected to own approximately 2.38% of the combined company. ksf is seeking to determine whether the merger and the process that led to it are adequate, and whether th.

MINGTENG INTERNATIONAL CORPORATION INC. ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2023

News

wuxi, china , may 15, 2024 /prnewswire/ -- mingteng international corporation inc. (nasdaq: mten) (the "company" or "mingteng international"), an automotive mold developer and supplier in china, today announced its financial results for the fiscal year ended december 31, 2023. mr. yingkai xu, chairman and chief executive officer of mingteng international, remarked, "we are delighted to present our financial results for fiscal year 2023.

IMPORTANT SHAREHOLDER ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST MACROGENICS, INC. AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

News

los angeles, ca / accesswire / may 18, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of macrogenics, inc. ("macrogenics" or "the company") (nasdaq:mgnx) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

CRACKER BARREL PROVIDES UPDATE ON STRATEGIC TRANSFORMATION PLAN AND ANNOUNCES CAPITAL ALLOCATION CHANGES TO DRIVE SUSTAINABLE LONG-TERM VALUE CREATION

News

organic growth investments expected to accelerate financial performance in late fiscal 2026 and into fiscal 2027 company provides update on third and fourth quarter fiscal 2024 lebanon, tenn., may 16, 2024 /prnewswire/ -- cracker barrel old country store, inc. ("cracker barrel" or the "company") (nasdaq: cbrl) today provided an update on its strategic transformation plan and announced changes to its capital allocation.

MULLEN REPORTS Q2 2024 FISCAL QUARTER RESULTS

News

positive stockholders' equity of $117,414,643 as of march 31, 2024 company has additional $150 million in capital commitments to support the scaling of commercial ev operations brea, calif., may 14, 2024 (globe newswire) -- -- via ibn -- mullen automotive, inc. (nasdaq: muln) (“mullen” or the “company”), an electric vehicle (“ev”) manufacturer, today announces financial results for the three and six months ended march 31, 2024, and a business update.

SUNPOWER RECEIVES NOTIFICATION OF DEFICIENCY FROM NASDAQ RELATED TO DELAYED FILING OF ANNUAL REPORT ON FORM 10-K

News

richmond, calif. , march 21, 2024 /prnewswire/ -- sunpower (nasdaq:spwr) received on march 20, 2024, a notice (the "notice") from the nasdaq stock market llc ("nasdaq") indicating that the company is not in compliance with nasdaq listing rule 5250(c)(1) (the "listing rule"), which requires timely filing of all required periodic financial reports with the sec, as a result of not having timely filed the form 10-k with the sec, as described more fully in the company's notification of late filing on form 12b-25 filed with the sec on february 29, 2024.

CHARLES & COLVARD ANNOUNCES REVERSE STOCK SPLIT

News

research triangle park, n.c., may 15, 2024 /prnewswire/ -- charles & colvard, ltd.

SCHOLAR ROCK REPORTS NEW EMPLOYEE INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

News

cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk; the “company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 102,150 shares of its common stock to six newly hired employees, consisting of inducement stock options to pur.

AMERICAN ONCOLOGY NETWORK APPOINTS NEW BOARD MEMBER

News

fort myers, fla., may 16, 2024 (globe newswire) -- american oncology network (aon) (nasdaq: aonc), one of the nation's fastest-growing networks of community oncology practices, is pleased to announce the appointment of william “bill” j.

UPDATE ON THE BRAZILIAN MERGER REVIEW PROCESS FOR THE SALE OF TERPHANE TO OBEN GROUP

News

richmond, va.--(business wire)--as previously announced, on september 1, 2023, tredegar corporation (nyse: tg) entered into a definitive agreement to sell its flexible packaging films (“terphane”) business to oben group. completion of the sale is contingent upon the satisfaction of customary closing conditions, including the receipt of certain competition filing approvals by authorities in brazil. tredegar announced today that, as part of the brazilian merger review process regarding the sale o.

KODIAK SCIENCES ANNOUNCES RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS

News

palo alto, calif. , may 15, 2024 /prnewswire/ -- kodiak sciences inc. (nasdaq: kod), today reported business highlights and financial results for the quarter ended march 31, 2024.

KIRBY MCINERNEY LLP ANNOUNCES INVESTIGATION OF SHAREHOLDER CLAIMS AGAINST TREACE MEDICAL CONCEPTS, INC. (TMCI)

News

new york--(business wire)-- #investigation--the law firm of kirby mcinerney llp is investigating potential claims against treace medical concepts, inc. (“treace” or the “company”) (nasdaq: tmci). the investigation concerns whether treace and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [click here to learn more about the investigation] on may 7, 2024, treace issued a press release reporting its financial results for the first quarter o.

AXIL SIGNS AGREEMENT WITH KINSEY'S FOR DISTRIBUTION OF HEARING PROTECTION AND ENHANCEMENT PRODUCTS

News

los angeles, may 03, 2024 (globe newswire) -- axil brands, inc. (“axil,” “we,” “us,” “our,” or the “company”) (nyse american: axil), an emerging global consumer products company for axil® hearing protection and enhancement products, today announced its entry into a distribution agreement (“agreement”) with kinsey's inc. to distribute axil hearing protection and enhancement products including axil gs extreme 2.0®, xcor®, xcor digital®, and the trackr™ series hearing solutions.

U POWER ANNOUNCES FILING OF 2023 ANNUAL REPORT WITH THE SEC

News

shanghai , may 16, 2024  /prnewswire/ -- u power limited (nasdaq: ucar) (the "company" or "u power"), a vehicle sourcing services provider with a vision to becoming a comprehensive electric ev battery power solution provider in china, today announces that on may 15, 2024, the company filed its 2023 annual report (20-f) with the u.s. securities and exchange commission (the "sec"). 2023 financial highlights total net revenues increased by 153.5% year over year to rmb19.8 million (us$2.8 million) in 2023.

NFT LTD. ANNOUNCES 1 FOR 50 REVERSE SHARE SPLIT

News

hong kong, april 11, 2024 (globe newswire) -- nft ltd. (nyse american: mi) ("company" or "nft", formerly known as takung art co., ltd.), as an emerging online trading platform operator of international art and collectibles today announced that a 1 for 50 reverse split of its class a ordinary shares and class b ordinary shares was approved by the company's shareholders on march 18, 2024 and is expected to become effective on or around april 12, 2024 (the “reverse split”).

VACASA TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9, 2024

News

portland, ore.--(business wire)--vacasa (nasdaq: vcsa), north america's leading vacation rental management platform, plans to report first quarter 2024 financial results after market close on thursday, may 9, 2024, followed by a conference call to discuss its results at 2:00 p.m. pt / 5:00 p.m. et the same day. chief executive officer rob greyber and chief financial officer bruce schuman will host the conference call. a link to the live webcast will be made available on vacasa's investor relati.

IZEA REPORTS Q1 2024 REVENUE OF $7.0 MILLION

News

orlando, fla., may 15, 2024 (globe newswire) -- izea worldwide, inc. (nasdaq: izea), the premier provider of influencer marketing technology, data, and services for the creator economy, reported its financial and operational results for the first quarter ended march 31, 2024.

CARMELL ANNOUNCES SUCCESSFUL CLOSING OF $3.0 MILLION PRIVATE PLACEMENT

News

pittsburgh, april 11, 2024 (globe newswire) -- carmell corporation (nasdaq: ctcx), a bio-aesthetics company focused on skin and hair health (“carmell”, the “company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors (the “private placement”). the company received gross proceeds from the private placement of $3 million, excluding offering expenses.

INCANNEX COMPLETE SUCCESSFUL PRE-IND MEETING WITH THE FDA FOR CANNQUIT-O FOR TREATMENT OF OPIOID USE DISORDER

News

melbourne, australia and new york, may 07, 2024 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (incannex or the company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-ind (investigational new drug) meeting with the u.s. food and drug administration (fda) regarding the development of cannquit-o for treatment of opioid use disorder (oud).

LEVI & KORSINSKY NOTIFIES ALTIMMUNE, INC. INVESTORS OF A CLASS ACTION LAWSUIT AND UPCOMING DEADLINE - ALT

News

new york, ny / accesswire / may 17, 2024 / if you suffered a loss on your altimmune, inc. (nasdaq:alt) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=80508&wire=1 or contact joseph e. levi, esq.

MORPHIC ANNOUNCES CORPORATE HIGHLIGHTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER 2024

News

morf ends 1q24 with $659 million, cash into 2h27; phase 2b study of morf-057 in uc continues on target; anticipate garnet phase 2 in crohn's to begin 2q

GROWGENERATION ANNOUNCES CHANGE TO BOARD OF DIRECTORS

News

denver--(business wire)--growgeneration corp. (nasdaq: grwg) (“growgen” or the “company”), one of the largest retailers and distributors of specialty hydroponic and organic gardening products in the united states, today announced that paul ciasullo is retiring and therefore resigning from the company's board of directors (the “board”), effective april 23, 2024. in conjunction with this announcement, starlett (star) carter has been appointed to the board, effective april 25, 2024, to fill the va.

LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF NOVAVAX, INC. (NVAX) AN UPCOMING CLAIMS DEADLINE IN A CLASS ACTION SETTLEMENT

News

new york, ny / accesswire / may 16, 2024 / levi & korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against novavax, inc. (nasdaq:nvax). the settlement provides for a fund of $47,000,000 to benefit class members.

BIT ORIGIN LTD EXPLORES THE USE OF ARTIFICIAL INTELLIGENCE IN CRYPTO MINING

News

new york, april 04, 2024 (globe newswire) -- bit origin ltd (nasdaq: btog) ("bit origin" or the "company"), an emerging growth company engaged in the crypto mining business with diversified expansion strategies, today announces that it actively explores the use of artificial intelligence (ai) in crypto mining.

ALPHA TECHNOLOGY GROUP LIMITED REPORTS 2023 FINANCIAL YEAR RESULTS

News

hong kong , feb. 1, 2024 /prnewswire/ -- alpha technology group limited (the "company" or "alpha")(nasdaq: atgl), a holding company incorporated in the british virgin islands that currently provides cloud-based it solution services through its operating subsidiaries, techlution service limited and neural sense limited (collectively, "operating subsidiaries"), today reported its financial results for the fiscal year ended september 30, 2023. fiscal year 2023 financial highlights: revenues increased by hk$4.27 million (approximately us$0.55 million), or 96.55%, from hk$4.42 million for the year ended september 30, 2022 to hk$8.69 million (approximately us$1.11 million) for the year ended september 30, 2023.

CANDEL THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

News

needham, mass., may 14, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended march 31, 2024, and provided a corporate update.

TRAVERE THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

News

san diego, may 15, 2024 (globe newswire) --  travere therapeutics, inc. (nasdaq: tvtx) today announced that on may 10, 2024, the compensation committee of its board of directors granted inducement equity grants covering an aggregate of 51,500 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or rsus, covering an aggregate of 26,500 shares of its common stock. these inducement stock options and inducement rsus are subject to the terms of travere's 2018 equity incentive plan (“2018 plan”), but were granted outside of the 2018 plan and were granted as inducements material to the new employees entering into employment with travere in accordance with nasdaq listing rule 5635(c)(4).

TPI COMPOSITES, INC. ANNOUNCES FIRST QUARTER 2024 EARNINGS RESULTS – RESULTS IN-LINE WITH COMPANY EXPECTATIONS; REITERATE FULL YEAR 2024 FINANCIAL GUIDANCE

News

scottsdale, ariz., may 02, 2024 (globe newswire) -- tpi composites, inc. (nasdaq: tpic), today reported financial results for the first quarter ended march 31, 2024.

AERWINS TECHNOLOGIES ANNOUNCES ADDITIONAL STAFF DETERMINATION

News

los angeles, ca, april 23, 2024 (globe newswire) -- aerwins technologies inc. (nasdaq: awin) (“aerwins” or “the company”) today announced that on april 17, 2024, the company received an additional staff delisting determination (the “additional staff determination”) from the listing qualifications department of the nasdaq stock market llc (“nasdaq”). the additional staff determination noted that the company is now delinquent in filing its form 10-k for the period ended december 31, 2023 (the “form 10-k”), which additional delinquency may serve as a separate basis for the delisting of the company's securities from nasdaq. the additional staff determination notified the company that the nasdaq hearings panel (the “panel”) will consider this matter in their decision regarding the company's continued listing on the nasdaq capital market and that it should present its views with respect to this additional deficiency to the panel in writing no later than april 24, 2024.

MAXEON SOLAR TECHNOLOGIES, LTD. BEING INVESTIGATED ON BEHALF OF MAXEON SOLAR TECHNOLOGIES, LTD.

News

new york, ny / accesswire / may 16, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of maxeon solar technologies, ltd. ("maxeon solar technologies, ltd.

ESPERION RECEIVES FIVE YEAR PATENT EXTENSION FOR BEMPEDOIC ACID, CONTAINED IN NEXLETOL® AND NEXLIZET®

News

ann arbor, mich., may 14, 2024 (globe newswire) -- esperion (nasdaq: espr) announced today that the u.s. patent and trademark office (uspto) issued a u.s. patent term extension (pte) certificate for bempedoic acid, which is contained in nexletol® (bempedoic acid) tablets and nexlizet® (bempedoic acid and ezetimibe) tablets. the certificate extends the term of u.s. patent no. 7,335,799 by five years through december 3, 2030. the pte certificate was granted under the patent restoration provisions of the drug price competition and patent term restoration act of 1984.

ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER ENDED MARCH 31, 2024

News

combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in psa in phase 1 dose escalation in patients with mcrpc naïve to second generation antiandrogens, including 81% of patients achieving psa90, 69% of patients achieving psa90 in less than 90 days, and 63% of patients achieving psa

INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION (PRAGUE) TO PRESENT ON SUCCESSFUL USE OF APPLIED DNA'S LINEA DNATM FOR THE NON-VIRAL MANUFACTURE OF CAR T-CELL THERAPY FOR REFRACTORY AML

News

stony brook, ny / accesswire / may 13, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, and the institute of hematology and blood transfusion (úhkt/ihbt) today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and cost-effective production of clinical-grade (gmp) car t-cell therapies has been accepted for presentation at the prestigious european hematology association 2024 hybrid congress to be held in madrid, spain from june 13 - 16, 2024. accepted abstracts will be available on the congress' website starting on may 14, 2024.

BIOATLA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

News

san diego, may 14, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the first quarter ended march 31, 2024, and provided highlights on its clinical programs.

ROSEN, A TRUSTED AND LEADING LAW FIRM, ENCOURAGES MALIBU BOATS, INC. INVESTORS TO SECURE COUNSEL BEFORE IMPORTANT DEADLINE IN SECURITIES CLASS ACTION - MBUU

News

new york , may 17, 2024 /prnewswire/ -- why: rosen law firm, a global investor rights law firm, reminds purchasers of securities of malibu boats, inc. (nasdaq: mbuu) between november 4, 2022 and april 11, 2024, both dates inclusive (the "class period"), of the important june 28, 2024 lead plaintiff deadline. so what: if you purchased malibu boats securities during the class period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

News

marks progress across key clinical and corporate goals strengthened balance sheet with $3.5 million conference call to be held today at 8:30 a.m. et houston, may 15, 2024 (globe newswire) -- bio-path holdings, inc., (nasdaq:bpth), a biotechnology company leveraging its proprietary dnabilize® antisense rnai nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended march 31, 2024 and provided an update on recent corporate developments.

ENGENE ANNOUNCES THE ELECTION OF PAUL HASTINGS AND WOUTER JOUSTRA TO ITS BOARD OF DIRECTORS

News

boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn or “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral lead program eg-70 is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced the election of paul hastings and wouter joustra as new members of its board of directors at the company's 2024 annual meeting of shareholders. shareholders also reelected incumbent director lota zoth. each will serv.

KBRA ASSIGNS PRELIMINARY RATINGS TO SUNNOVA HESTIA II ISSUER, LLC SOLAR LOAN BACKED NOTES, SERIES 2024-GRID1

News

new york--(business wire)-- #creditratingagency--kbra assigns preliminary ratings to two classes of notes issued by sunnova hestia ii issuer, llc solar loan backed notes, series 2024-grid1, a $168.9 million residential solar loan abs transaction. this transaction represents the second securitization under the hestia program, which contains a partial loan guarantee provided by the u.s. department of energy. projects funded under project hestia are, in part, to provide loans for clean energy systems to disadvantaged c.

JIN MEDICAL INTERNATIONAL LTD. ENTERS INTO MEMORANDUM OF UNDERSTANDING TO ACQUIRE MEDICAL EQUIPMENT SHARING PLATFORM

News

changzhou city, china, dec. 14, 2023 (globe newswire) -- jin medical international ltd. (the "company" or “jinmed”) (nasdaq: zjyl), a cayman islands holding company with chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced the signing of a preliminary memorandum of understanding (mou) with jiangsu zhongjin kanglu information technology co., ltd. ("zhongjin kanglu") to acquire all or a partial stake in zhongjin kanglu.

SIGHT SCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS FULL YEAR 2024 FINANCIAL GUIDANCE

News

menlo park, calif., may 02, 2024 (globe newswire) -- sight sciences, inc. (nasdaq: sght) ("sight sciences" or the "company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended march 31, 2024, and reaffirmed financial guidance for full year 2024.

ICAHN ENTERPRISES L.P. ANNOUNCES UPSIZING AND PRICING OF SENIOR NOTES

News

sunny isles beach, fla. , may 13, 2024 /prnewswire/ -- icahn enterprises l.p.

VIRIDIAN THERAPEUTICS TO PARTICIPATE IN UPCOMING MAY INVESTOR CONFERENCES

News

waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming investor conferences in may: 2024 rbccm global healthcare conference (new york, ny): presentation on tuesday, may 14, 2024, at 8:30 a.m. et. bofa securities 2024 health care conference (las vegas, nv): present.

RENEW AND SOCIETE GENERALE SIGN MOU FOR USD 1 BILLION TO BROADEN COLLABORATION ON ENERGY TRANSITION PROJECTS

News

new delhi--(business wire)---- $rnw #europeanbank--renew and societe generale sign mou for usd 1 billion to broaden collaboration on energy transition projects.

FIRST US BANCSHARES, INC. REPORTS FIRST QUARTER 2024 EARNINGS

News

birmingham, ala. , april 24, 2024 /prnewswire/ -- first quarter highlights: net income diluted earnings per share return on average assets (annualized) return on average common equity (annualized) return on average tangible common equity (annualized) (1) loans to deposits $2.1 million $0.34 0.80 % 9.25 % 10.08 % 87.2 % first us bancshares, inc. (nasdaq: fusb) (the "company"), the parent company of first us bank (the "bank"), today reported net income of $2.1 million, or $0.34 per diluted share, for the quarter ended march 31, 2024 ("1q2024"), compared to $2.3 million, or $0.36 per diluted share, for the quarter ended december 31, 2023 ("4q2023") and $2.1 million, or $0.33 per diluted share, for the quarter ended march 31, 2023 ("1q2023").

ALLOGENE THERAPEUTICS ANNOUNCES PRICING OF $110 MILLION OFFERING OF COMMON STOCK

News

south san francisco, calif., may 13, 2024 (globe newswire) -- allogene therapeutics, inc. (nasdaq: allo), a clinical-stage biotechnology company pioneering the development of allogeneic car t (allocar t™) products for cancer and autoimmune disease, today announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share. the gross proceeds from this offering are expected to be approximately $110 million, before deducting the underwriting discount and commissions and estimated offering expenses payable by allogene.

TRUPANION COMMENTS ON RATE FILING APPROVAL IN CALIFORNIA

News

seattle, may 17, 2024 (globe newswire) -- trupanion, inc. (nasdaq: trup) today provided the following update on its rate filing approval status in california.

AMBRY GENETICS AND PACBIO ANNOUNCE COLLABORATION TO SEQUENCE UP TO 7,000 HUMAN GENOMES AIMED AT PROVIDING ANSWERS FOR FAMILIES BATTLING RARE DISEASES

News

consortium selects leading genomics companies to support pediatric mendelian genomics research center program aliso viejo, calif. and menlo park, calif.

BIOAFFINITY TECHNOLOGIES REPORTS RECORD Q1 REVENUE DRIVEN BY ACCELERATING GROWTH OF CYPATH® LUNG SALES AND INCREASED LABORATORY VOLUMES

News

san antonio--(business wire)-- #biaf--bioaffinity technology reports record q1 2024 revenue driven by accelerating sales of lung cancer diagnostic cypath lung.

MOBIX LABS, INC. ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS

News

irvine, calif.--(business wire)--mobix labs, inc. (nasdaq: mobx) (“mobix labs” or the “company”), a fabless semiconductor company developing disruptive next-generation connectivity solutions for wired, wireless 5g, military, defense, aerospace, and medical industries, today announced its financial results for the fiscal second quarter ended march 31, 2024. “i am excited about march quarter's execution on foundational milestones including our entering into a definitive agreement for the synergis.

ZYVERSA THERAPEUTICS REPORTS FIRST QUARTER, 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

News

key highlights: second research site selected to enhance enrollment in the phase 2a clinical trial for cholesterol efflux mediatortm var 200 in patients with diabetic kidney disease planned to begin h1-2024. glp toxicology studies for inflammasome asc inhibitor ic 100 scheduled to begin h1-2024, with planned investigational new drug (ind) submission q4-2024, and phase 1 clinical trial initiation q1-2025.atherosclerosis preclinical data readout for inflammasome asc inhibitor ic 100 on schedule for h1-2024.

SWVL RECORDS $3.1M NET PROFIT, 13% NET MARGIN, AND AN EIGHTFOLD GROWTH IN GROSS PROFIT

News

8x gross profit growth year on year to $4.1 million achieved cash flow positivity, with self-funded growth profitable growth drove earnings per share from continuing operations to $0.61 strong balance sheet with no debt and more than doubled the positive equity value compared to 2022 dubai, united arab emirates, april 30, 2024 (globe newswire) -- swvl holdings corp (“swvl” or the “company”) (nasdaq: swvl), a technology provider for enterprise and government mobility solutions with a global footprint, announces a significant achievement in its financial performance for the fiscal year 2023. the company has successfully delivered positive net profit and cashflow for the full year.

SENSUS HEALTHCARE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS WITH REVENUES UP MORE THAN THREE-FOLD

News

revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; a djusted ebitda (a non-gaap measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarter launched the “fair deal agreement” recurring revenue program to provide an equipment placement option and complement the fair market value lease program for srt systems conference call begins at 4:30 p.m. eastern time today boca raton, fla.

INFOBIRD CO., LTD ANNOUNCES DELAY IN EFFECTIVE DATE OF REVERSE SPLIT TO MARCH 4 ,2024

News

hong kong , feb. 26, 2024 /prnewswire/ -- infobird co., ltd (nasdaq: ifbd) ("infobird" or the "company"), a software-as-a-service provider of innovative ai-powered, or artificial intelligence enabled, customer engagement solutions, today announced that the company is amending the effective date for its reverse stock split to monday march 4, 2024 to begin trading on a split-adjusted basis when the market opens, due to an unanticipated delay in obtaining necessary regulatory clearances. previously, the company had planned for its reverse split to become effective after the close of business on monday, february 26, 2024, and had expected the ordinary shares to begin trading on a split-adjusted basis when the market opened the following day, tuesday, february 27, 2024.

STRONGHOLD ANNOUNCES FIRST QUARTER 2024 OPERATING AND FINANCIAL RESULTS

News

new york, may 02, 2024 (globe newswire) -- stronghold digital mining, inc. (nasdaq: sdig) (“stronghold”, the “company”, or “we”) today announced financial and operational results for the first quarter of 2024 and provided other strategic updates: recent financial highlights the company generated revenues of $27.5 million during the first quarter of 2024, up 27% sequentially and 59% year-over-year. revenues comprised $26.7 million from cryptocurrency operations, $0.7 million from the sale of energy, and $0.1 million from other activities.

IMPORTANT SHAREHOLDER ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST CRYOPORT, INC. AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

News

los angeles, ca / accesswire / may 18, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of cryoport, inc. ("cryoport" or "the company") (nasdaq:cyrx) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

BIGLARI HOLDINGS INC. NEWS RELEASE

News

san antonio, tx , may 10, 2024 /prnewswire/ -- biglari holdings inc. (nyse: bh.a; bh) announces its results for the first quarter of 2024. biglari holdings inc.'s earnings for the first quarter of 2024 and 2023 are summarized below.

SHAREHOLDER RIGHTS ADVOCATES AT LEVI & KORSINSKY INVESTIGATE FORWARD AIR CORPORATION (FWRD) REGARDING POSSIBLE SECURITIES FRAUD VIOLATIONS

News

new york, ny / accesswire / may 9, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of forward air corporation ("forward air") (nasdaq:fwrd) concerning possible violations of federal securities laws. forward air disclosed its financial performance for the first quarter of 2024, following the market closure on may 8, 2024.

IMPORTANT SHAREHOLDER ALERT: THE SCHALL LAW FIRM ENCOURAGES INVESTORS IN GOODRX HOLDINGS, INC. WITH LOSSES TO CONTACT THE FIRM

News

los angeles, ca / accesswire / may 18, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against goodrx holdings, inc. ("goodrx" or "the company") (nasdaq:gdrx) for violations of 10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between september 23, 2020 and november 8, 2022, inclusive (the "class period"), are encouraged to contact the firm before june 21, 2024.

NANOVIRICIDES HAS FILED ITS QUARTERLY REPORT

News

nv-387 advancing to phase ii clinical trial for the treatment of rsv infection shelton, ct / accesswire / may 15, 2024 / nanoviricides, inc. (nyse american:nnvc) (the "company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its quarterly report on form 10-q for the fiscal second quarter ending march 31, 2024 with the securities and exchange commission (sec) on tuesday, may 14, 2024. the report can be accessed at the sec website by searching for the company's filings.

SNDL REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS

News

the company reports increased revenue year-over-year and record profit margin calgary, ab , may 9, 2024 /prnewswire/ - sndl inc. (nasdaq: sndl) ("sndl" or the "company") reported its financial and operational results for the first quarter ended march 31, 2024. all financial information in this press release is reported in millions of canadian dollars unless otherwise indicated.

PUMA BIOTECHNOLOGY REPORTS FIRST QUARTER FINANCIAL RESULTS

News

los angeles--(business wire)--puma biotechnology will report its financial results for 1q-2024 after the close and host a conference call at 1:30 p.m. pt on may 2.

ENANTA PHARMACEUTICALS TO PARTICIPATE AT THE JMP SECURITIES LIFE SCIENCES CONFERENCE

News

watertown, mass.--(business wire)--enanta pharmaceuticals, inc. (nasdaq:enta), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that jay r. luly, ph.d., president and chief executive officer, and tara l. kieffer, ph.d., chief product strategy officer, will participate in a fireside chat at the jmp securities life sciences conference on may 14, 2024 at 10:00 a.m. et in new york, ny. a live webcast of the ev.

SYNCHRONOSS TECHNOLOGIES REPORTS FIRST QUARTER 2024 RESULTS

News

q1 revenue grew to $43.0 million, surpassing 91% recurring revenue gaap gross margin expands to 67%; adjusted gross margin rises to 76% streamlined operations improve profitability with net income increasing by $15.7 million year-over-year; eps improved to $0.23 from $(1.39) in q1 2023; adjusted ebitda improved 78% to $10.9 million company reaffirms 2024 guidance bridgewater, n.j., may 07, 2024 (globe newswire) -- synchronoss technologies inc. (“synchronoss” or the “company”) (nasdaq: sncr), a global leader and innovator in personal cloud platforms, today reported financial results for its first quarter ended march 31, 2024.

BLACK DIAMOND THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

News

cambridge, ma, may 09, 2024 (globe newswire) -- black diamond therapeutics, inc. (nasdaq: bdtx), a clinical-stage oncology company developing masterkey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended march 31, 2024, and provided a corporate update.

ATHIRA PHARMA ANNOUNCES PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTION

News

bothell, wash., may 17, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the u.s. district court for the western district of washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled bushansky v. kawas et al., no. 2:22-cv-497 and houlihan v. kawas et al., no. 2:22-cv-620, pending before the court. the proposed settlement calls for athira to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards.

GYRE THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

News

phase 3 clinical trial evaluating f351 for the treatment of chb-associated liver fibrosis in the prc remains on track with data anticipated by early 2025 u.s. ind submission to evaluate f351 for the treatment of nash-associated liver fibrosis expected in late 2024; phase 2a trial expected to initiate in 2025 acquired the rights to complementary assets relating to nintedanib through gyre pharmaceuticals to improve competitiveness in the prc cash and cash equivalents totaled $29.8 million as of march 31, 2024 san diego, may 09, 2024 (globe newswire) -- gyre therapeutics (“gyre”) (nasdaq: gyre), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced financial results for the first quarter ended march 31, 2024, and provided a business update. “supported by sales of our market-leading ipf drug, etuary, gyre is well-positioned to advance multiple pipeline programs addressing organ fibrosis, including our phase 3 clinical trial of f351 in chb-associated liver fibrosis in the prc that is on track to report data by early 2025,” said han ying, ph.d.

APTORUM GROUP LIMITED REPORTS 2023 FISCAL YEAR END FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

News

new york & london--(business wire)--aptorum group limited (nasdaq: apm) (“aptorum group” or “we”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended december 31, 2023, and provided an update on corporate developments. mr. ian huen, chief executive officer and executive director of aptorum group, commented, “throughout 2023, we have maintained a.

GENEDX REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

News

reported first quarter 2024 revenue from continuing operations 1 of $61.5m with 96% year-over-year growth of exome and genome test revenue expanded first quarter 2024 adjusted gross margins 2 from continuing operations to 61% narrowed first quarter 2024 adjusted net loss 2 to $8.5m and delivered 71% year-over-year cash burn reduction raised guidance to deliver between $235m and $245m in fy 2024 revenue and reiterate path to profitability in 2025 genedx to host conference call today at 4:30 p.m. et stamford, conn.

FREIGHTCAR AMERICA, INC. REPORTS FIRST QUARTER 2024 RESULTS

News

company d eliver s 99% year-over-year revenue growth and record quarterly deliv eries for new plant

AC IMMUNE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

News

ac immune reports first quarter 2024 financial results and provides a corporate update landmark deal announced with takeda for aci-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion aci-24.060 abate phase 2 trial on track to report abeta-pet imaging results in q2 2024, evaluating amyloid plaque reduction after 6 months of anti-abeta active immunotherapy aci-7104.056 vacsyn phase 2 trial of anti-a-syn active immunotherapy in parkinson's disease (pd) on track for safety and immunogenicity interim data in h2 2024 three-year cash runway with chf 104.8 million at quarter end, plus $100 million upfront from takeda and the anticipated aci-35.030-related chf 25 million milestone lausanne, switzerland, may 13, 2024 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today reported results for the quarter ended march 31, 2024, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “we are thrilled to have announced today our agreement with takeda to advance aci-24.060 anti-abeta active immunotherapy in alzheimer's disease (ad).

ARCADIA BIOSCIENCES (RKDA) TO HOST INVESTOR CALL TO DISCUSS RECENT TRANSACTIONS

News

dallas--(business wire)--arcadia biosciences, inc.® (nasdaq: rkda), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will host a call for analysts and investors after market close on may 22, 2024. the company has scheduled a conference call for 4:30 p.m. eastern time (1:30 p.m. pacific time) to discuss recent strategic transactions. interested participants can join the conference call using the following options: an audio-only webcast of t.

CLEANCORE SOLUTIONS, INC. ANNOUNCES INSTALLATION OF POWER CADDY UNITS AT A MAJOR NORTHEASTERN INTERNATIONAL AIRPORT FOLLOWING SUCCESSFUL PILOT

News

reports rapid growth in sales pipeline across key verticals, including transportation, hospitality, manufacturing, education and more reports rapid growth in sales pipeline across key verticals, including transportation, hospitality, manufacturing, education and more

CIDARA THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

News

san diego, may 15, 2024 (globe newswire) -- cidara therapeutics, inc. (nasdaq: cdtx) (the company), a biotechnology company using its proprietary cloudbreak® platform to develop drug-fc conjugate (dfc) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended march 31, 2024, and provided an update on its corporate activities and product pipeline.

PRELUDE THERAPEUTICS TO PARTICIPATE IN CITIZENS JMP LIFE SCIENCES CONFERENCE

News

wilmington, del., may 09, 2024 (globe newswire) -- prelude therapeutics incorporated (prelude) (nasdaq: prld), a clinical-stage precision oncology company, announced today that the company will participate in the citizens jmp life sciences conference, taking place in new york city on may 13 and 14.

OKLO SIGNS MOU WITH ATOMIC ALCHEMY TO COLLABORATE ON ISOTOPE PRODUCTION

News

santa clara, calif.--(business wire)-- #advancedfission--oklo inc. (nyse: oklo) (“oklo” or the “company”), a fast fission clean power technology and nuclear fuel recycling company, is forming a strategic partnership with atomic alchemy inc. (“atomic alchemy”) to produce isotopes. this partnership will aim to combine oklo's work to build and operate fast reactors and fuel recycling expertise with atomic alchemy's expertise in isotope production to meet increasing demands for isotopes. isotopes are vital for many p.

APOGEE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 ATOPIC DERMATITIS TRIAL OF APG777, A NOVEL SUBCUTANEOUS HALF-LIFE EXTENDED ANTI-IL-13 ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS AND OTHER INFLAMMATORY DISEASES

News

interim clinical data from apg777 phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile

CORE MOLDING TECHNOLOGIES TO PARTICIPATE IN THE EF HUTTON ANNUAL GLOBAL CONFERENCE IN NYC

News

columbus, ohio, may 08, 2024 (globe newswire) -- core molding technologies, inc. (nyse american: cmt) (“core molding”, “core” or the “company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the united states, canada and mexico today announced that david duvall, president and ceo, and john zimmer, evp and cfo, will participate in the ef hutton annual global conference at the plaza hotel in new york city on may 15, 2024.

CURIS ANNOUNCES ADDITIONAL DATA FROM TAKEAIM LEUKEMIA STUDY

News

data update expands aml dataset from 5 to 30 patients lexington, mass. , may 14, 2024 /prnewswire/ -- curis, inc. (nasdaq: cris), a biotechnology company focused on the development of emavusertib (ca-4948), an orally available, small molecule irak4 inhibitor, today announced updated data from the ongoing takeaim leukemia study (ca-4948-102) in relapsed/refractory (r/r) aml to be presented at the asco and eha conferences.

SHAREHOLDERS THAT LOST MONEY ON SHOALS TECHNOLOGIES GROUP, INC.(SHLS) SHOULD CONTACT LEVI & KORSINSKY ABOUT PENDING CLASS ACTION - SHLS

News

new york, ny / accesswire / may 17, 2024 / if you suffered a loss on your shoals technologies group, inc. (nasdaq:shls) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/shoals-technologies-lawsuit-submission-form?prid=80523&wire=1 or contact joseph e. levi, esq.

IMPORTANT SHAREHOLDER ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST VERVE THERAPEUTICS, INC. AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM

News

los angeles, ca / accesswire / may 18, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of verve therapeutics, inc. ("verve" or "the company") (nasdaq:verv) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

PHARVARIS TO PRESENT CLINICAL AND NONCLINICAL DATA AT UPCOMING CONGRESSES

News

zug, switzerland, may 13, 2024 (globe newswire) -- pharvaris (nasdaq: phvs), a late-stage biopharmaceutical company developing novel, oral bradykinin b2 receptor antagonists to treat and prevent hereditary angioedema (hae) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th annual congress of international drug discovery science and technology (iddst); the 2024 eastern allergy conference (eac); and the european academy of allergy and clinical immunology (eaaci) congress 2024. details of the presentations are as follows:

SAB BIOTHERAPEUTICS APPOINTS JAY SKYLER, MD, TO THE BOARD OF DIRECTORS

News

miami, may 06, 2024 (globe newswire) -- sab biotherapeutics (nasdaq: sabs) (the “company” or “sab”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that jay skyler, md, macp, frcp has been appointed to the company's board of directors.

LUCAS ANNOUNCES FISCAL YEAR 2023 FINANCIAL RESULTS WITH 92.3% GROWTH, REACHING REVENUE AT $208M

News

new york, april 29, 2024 (globe newswire) -- lucas gc limited (nasdaq: lgcl) (“lucas” or the “company”), an artificial intelligence (the “ai”) technology-driven platform-as-a-service (the “paas”) company currently focusing on offering human capital management services, today announced its financial results for fiscal year of 2023. full year 2023 financial highlights revenues of rmb1,474 million (us$208 million), representing a 92.3% increase versus 2022.

INOVIO REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

News

bla submission on track for ino-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (rrp) planning initiation of confirmatory trial for ino-3107 based on fda feedback advancing plans for phase 3 trial of ino-3112 in combination with loqtorzitm (toripalimab-tpzi) as a potential treatment for oropharyngeal squamous cell carcinoma (opscc) based on fda feedback balance sheet strengthened with underwritten offering of common stock and pre-funded warrants completed in april 2024 cash runway projected into third quarter of 2025 plymouth meeting, pa. , may 13, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.